Danaher Corporation

Danaher Corporation

DHRNYSEHealthcare
$229.04
down -2.46 (-1.06%)

1-Year Price

+7.59% past year
Danaher Corporation (DHR) 1-year price chart: up 7.59% from $212.88 on Oct 2025 to $229.04 on Oct 2026. Closing range $161.91 to $242.05.

EquityGlimpse Score

Overall
5.3/10
Wide Moat

Strong, durable competitive advantages versus peers.

Growth
2

Valuation, profitability, financial health, dividend and sentiment scores for Danaher Corporation (DHR) are available to EquityGlimpse members.

Market Cap
161.01B
P/E Ratio
45.15
EPS
$5.11
52W High
$242.8
52W Low
$160.93
Volume
3.51M
Beta
0.8
Dividend Yield
0.54%
Fair value estimate: sign up to see
Is DHR over- or undervalued? Run DCF and multiples models on EquityGlimpse.
See fair value

Key Financial Metrics

Price to Sales
6.59
Price to Book
3.08
EV/EBITDA
25.30
Free CF per Share
$7.44
Op. CF per Share
$9.07
Debt to Equity
0.35
Gross Margin
60.93%
Net Margin
14.71%

About Danaher Corporation

Danaher Corporation is a diversified global technology and science company that specializes in developing, manufacturing, and distributing a wide array of professional, medical, industrial, and commercial products and services across the world. The organization is structured into three primary operating segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Within the Life Sciences segment, Danaher provides advanced instrumentation and solutions crucial for scientific research and development. This encompasses equipment like mass spectrometers, flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization tools, and microscopes, alongside genomics consumables and technologies vital for Gene and Cell Therapy. Additionally, it delivers bioprocess technologies, consumables, and related services, as well as sophisticated filtration, separation, and purification systems. Its diverse clientele includes pharmaceutical, biopharmaceutical, food and beverage, medical, and life sciences companies, in addition to universities, medical schools, research institutions, and various industrial manufacturers. The Diagnostics segment is dedicated to furnishing essential tools for healthcare. Its offerings range from comprehensive systems for chemistry, immunoassay, microbiology, and automation to products for hematology, molecular, acute care, and pathology diagnostics. This segment equips hospitals, physicians' offices, reference laboratories, and other critical care settings with clinical instruments, reagents, consumables, software, and support services for accurate patient diagnosis and management. The Environmental & Applied Solutions segment addresses a broad spectrum of industrial and resource management requirements. It supplies instrumentation, consumables, software, services, and disinfection systems critical for the analysis, treatment, and management of various water types—including ultra-pure, potable, industrial, waste, ground, source, and ocean water—across residential, commercial, industrial, and natural resource applications. Furthermore, this segment delivers instruments, software, services, and consumables tailored for color and appearance management, packaging design and quality assurance, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. Established in 1969, the company was initially known as Diversified Mortgage Investors, Inc., before officially rebranding as Danaher Corporation in 1984. Its corporate headquarters are located in Washington, D.C.

CEO
Julie Sawyer Montgomery
Industry
Medical - Diagnostics & Research
Employees
59,000
IPO Date
1978-12-29
Country
US
Unlock Full Analysis

Get the complete picture on Danaher Corporation

Sign up for EquityGlimpse to access deep fundamental data, AI reports, valuation models, and real-time tracking for DHR and 8,500+ other stocks.

30 Years of Financials
Income statements, balance sheets, and cash flows with 70+ interactive charts
AI-Powered Analysis
Generate professional research reports with 15+ AI models
DCF Valuation
Run discounted cash flow models with customizable assumptions
Portfolio Tracking
Track real-time P&L, sector allocation, and dividend projections
Earnings Intelligence
Surprise tracking, revision momentum, and whisper estimates
Insider & Congress Trades
Monitor what insiders and Congress members are buying and selling

Starting at $8.25/month. 7-day free trial. Cancel anytime.